Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1084 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Canakinumab in addition to pembrolizumab and platinum-based chemotherapy for locally advanced or metastatic non-small-cell lung cancer (NSCLC)	Canakinumab (Ilaris; ACZ885) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Canakinumab for Schnitzler syndrome	Canakinumab (Ilaris; ACZ885)	Schnitzler syndrome	Immunology	2021	View \| Download
Canakinumab adjuvant therapy for treating completely resected non-small-cell lung cancer	Canakinumab (Ilaris; ACZ885)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Canakinumab (ILARIS) for Cardiovascular risk reduction – Add on therapy	Canakinumab (Ilaris; ACZ885)	Cardiovascular disease (CVD)	Cardiovascular System	2017	View \| Download
Canagliflozin for type 2 diabetes mellitus in children and adolescents	Canagliflozin (Invokana; canagliflozin hemihydrate)	Type 2 diabetes	Endocrine, nutritional and metabolic disorders	2023	View \| Download
Canagliflozin for chronic kidney disease in adult patients with type 2 diabetes mellitus	Canagliflozin (Invokana; canagliflozin hemihydrate)	Diabetic nephropathy	Endocrine Nutritional and Metabolic Disorders , Nephrology	2019	View \| Download
CAEL-101 for treating amyloid light chain amyloidosis	CAEL-101	Amyloid light chain amyloidosis	Endocrine Nutritional and Metabolic Disorders	2022	View \| Download
Cabozantinib with nivolumab and ipilimumab for previously untreated advanced or metastatic renal cell carcinoma	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2023	View \| Download
Cabozantinib with atezolizumab for treating metastatic castration-resistant prostate cancer after one novel hormonal therapy	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Prostate cancer	Haematological Cancer and Lymphomas , Oncology	2023	View \| Download
Cabozantinib in combination with atezolizumab for advanced hepatocellular carcinoma –first line	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download